Riskpilot← Back to searchSign inGet full accessDNE PHARMA AS
ASActiveOrg 991741208Karihaugveien 22, 1086 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 20075 employees
Revenue 2024
NOK 62,3M
+15% vs 2023
EBITDA margin
22.8%
+55% vs 2023
Equity ratio
55.3%
Financial strength
Net profit 2024
NOK 8,9M
+35% vs 2023
| Revenue | NOK 62,3M | +15% |
| EBITDA | NOK 14,2M | +55% |
| Net profit | NOK 8,9M | +35% |
| Total assets | NOK 96,5M | +16% |
| Equity | NOK 53,4M | -10% |
| Employees | 5 | — |
Legal name
DNE PHARMA AS
Org number
991741208
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
17. oktober 2007
Share capital
NOK 142 231
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap eller daglig leder og styrets leder i fellesskap.
Company purpose
Selv, gjennom hel eller deleide selskaper eller ved samarbeide med andre virksomheter, å drive handel og utvikling med og av farmasøytiske produkter, herunder legemidler, samt annen forretningsmessig virksomhet forbundet hermed.
Address
Karihaugveien 22, 1086 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57 347 | 144 352 | 135 321 | 89 492 | 52 786 | 44 572 | 28 168 | 31 713 | 40 374 | 46 745 | 54 192 | 62 328 |
| Staff expenses | −16 929 | −40 752 | −40 793 | −18 934 | −6 292 | −10 415 | −10 867 | −7 310 | −8 203 | −7 165 | −7 590 | −8 519 |
| EBITDA | 2 785 | 10 165 | 1 485 | 12 451 | 11 875 | 14 782 | −6 656 | 680 | 6 796 | 9 102 | 9 159 | 14 240 |
| Depreciation & amort. | −3 960 | −0 | −0 | −551 | −485 | −249 | −0 | −70 | −0 | −0 | −0 | −2 933 |
| EBIT | −1 175 | 10 165 | 1 485 | 11 899 | 11 390 | 14 533 | −6 656 | 610 | 6 796 | 9 102 | 9 159 | 11 307 |
| Net financials | −659 | −6 523 | −6 239 | −4 097 | 36 | 544 | 2 105 | −14 644 | −511 | −540 | −749 | 102 |
| Profit before tax | −1 833 | 3 642 | −4 754 | 7 802 | 11 426 | 15 077 | −4 550 | −14 034 | 6 285 | 8 562 | 8 410 | 11 409 |
| Tax | −677 | 182 | −538 | 1 763 | 2 766 | −6 399 | −990 | 337 | 1 285 | 1 725 | 1 803 | 2 511 |
| Net profit | −1 156 | 3 460 | −4 216 | 6 039 | 8 660 | 21 476 | −3 561 | −14 371 | 5 000 | 6 837 | 6 607 | 8 898 |
| Item | 2012 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 32 920 | 77 904 | 59 161 | 41 623 | 39 696 | 107 614 | 62 151 | 76 926 | 75 668 | 91 487 | 83 399 | 96 529 |
| Equity | 8 512 | 6 505 | 22 953 | 17 168 | 14 058 | 47 469 | 43 908 | 41 296 | 46 026 | 52 863 | 59 470 | 53 368 |
| Long-term debt | 10 640 | 12 247 | 13 227 | 0 | 0 | 4 759 | 0 | 6 727 | 6 619 | 6 684 | 7 063 | 7 313 |
| Short-term debt | 12 616 | 53 843 | 21 593 | 24 255 | 25 439 | 49 887 | 14 451 | 26 054 | 20 220 | 29 635 | 16 243 | 35 718 |
| Total debt | 23 256 | 66 090 | 34 820 | 24 255 | 25 439 | 54 645 | 14 451 | 32 781 | 26 839 | 36 319 | 23 305 | 43 031 |
EBITDA margin
22.8%
This company
15.8%
Market median
+44% vs market
20122024
Equity ratio
55.3%
This company
38.2%
Market median
+45% vs market
20122024
Return on equity
16.7%
This company
18.4%
Market median
+9% vs market
20122024
Net profit margin
14.3%
This company
8.1%
Market median
+77% vs market
20122024
Asset turnover
0.65×
This company
1.12×
Market median
-42% vs market
20122024
Debt / equity
0.81×
This company
0.62×
Market median
+31% vs market
20122024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
GO Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2023 | — | — | |
| Chairman | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Farma Investment As | Company | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Calin Invest As
DNE PHARMA AS Board members of DNE PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Geir Ove Engeset | Chief Executive Officer | 0 companies |
| Esther Elisabeth Paust | Chairman | 0 companies |
| Geir Ivar Simonsen | Chairman | 0 companies |